{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "CNC",
  "name": "Centene Corporation",
  "url": "https://orbyd.app/dossiers/CNC/",
  "json_url": "https://orbyd.app/dossiers/CNC.json",
  "status": "HELD",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Post-print recovery extended: $65.77 close on 2026-08-07 (+2.45%), above the 20-day and 50-day levels marked on 08-04, with the $69.36 52-week high in view. Two dated events inside four sessions — CMS's 3:00pm EDT 2026-08-12 PY2027 rate lock (HealthCare.gov states only; SBE states run to 10-15) and the 08-13 $500M par redemption. Theme still SATURATED: eight post-print target raises, zero cuts, consensus $71.67 scored at 8.97% upside.",
  "invalidation_trigger": "A weekly close below $63 undoes the 50-day zone reclaimed 2026-08-03 and ends the post-print higher-low sequence; a weekly close below $56 also loses the July shelf. Secondarily, 2026-08-12 passing with the 2027 rate position unchanged, or a Q3 print (~2026-10-27, est.) trimming the more-than-$4.80 FY guide.",
  "catalyst_date": "2026-08-12",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Adjusted EPS excludes amortization of acquired intangibles and other items: FY2026 GAAP guidance is more than $3.11 against adjusted more than $4.80.",
    "FY2025 carried a $6,723M goodwill impairment, a $513M Magellan impairment and a $(13.53) GAAP diluted loss, so trailing GAAP earnings stay negative until that quarter rolls off.",
    "Marketplace risk-adjustment transfers settle with a lag, so prior-benefit-year true-ups can swing a single quarter's EPS by tens of cents either way.",
    "Premium and service revenue ran $44.4B in Q2 2026 on a thin underwriting spread; point moves in the health benefits ratio dominate EPS more than membership headlines.",
    "Calendar fiscal year: Q3 results are typically reported in late October and full-year results in early February.",
    "Revenue is set largely by state Medicaid rate cycles and CMS rulemaking, so regulatory calendar dates move the P&L more than company-level execution."
  ],
  "body_markdown": "## Current Thesis\n\nThe post-print bid has kept extending. That clears both moving-average levels as they stood on 2026-08-04 — the 20-day at $65.16 and the 50-day at $63.85 — and puts the stock inside a 52-week range of $25.08–$69.36 at a $32.49B market cap. The two intervening sessions are not restated here. The only Centene release dated in that gap was a $350,000 flood-relief commitment from Superior HealthPlan and the Centene Foundation on 2026-08-05, so no company disclosure is attached to the 08-07 move.\n\nThe leg being underwritten is unchanged: a shrinking book converting a repaired underwriting margin into per-share value, with 2027 volume unresolved until December. Two dated events now sit inside four sessions. CMS requires every rate filing containing a qualified health plan to be finalized by 3:00 p.m. EDT on 2026-08-12 — but that deadline binds filings in states on the HealthCare.gov platform; state-based exchanges off that platform set their own date, no later than 2026-10-15 (CMS revised PY2027 QHP Data Submission and Certification Timeline Bulletin). Marketplace price for 2027 therefore locks in two stages, not one. Second, Centene delivered notice on 2026-07-29 to redeem $500,000,000 of its 4.25% notes due 2027-12-15 on 2026-08-13 at par plus accrued interest, leaving roughly $568,664,000 outstanding (Form 8-K, 2026-07-29).\n\n**Theme status: SATURATED.** Dating it: eight sell-side target revisions since the 2026-07-28 print, all raises, no cuts — and the two most recent are the two lowest, JP Morgan $67 with a Neutral on 2026-08-04 and Baird $66 with a Neutral on 2026-07-29, both struck near where the stock already traded. Consensus across 21 analysts is $71.67, which stockanalysis.com scored as 8.97% upside on 2026-08-07; early-August consensus roundups put the panel at 8 Strong Buy, 12 Hold, 1 Strong Sell. Targets are following the tape.\n\n## Bull Case\n\n- Q2 2026 (2026-07-28): adjusted EPS $2.51 versus $1.08 consensus; revenue $53.579B versus $47.617B; net income $1.09B against a $253M loss a year earlier.\n- FY2026 adjusted EPS guidance raised to more than $4.80 from more than $3.40 (consensus $3.52); revenue $193.5–197.5B; full-year HBR 90.5%–91.3%; GAAP EPS more than $3.11.\n- Every segment cost ratio improved in Q2: consolidated HBR 89.6% from 93.0%; Commercial/ACA 79.2% from 90.6%; Medicaid 93.9% from 94.9%; Medicare 89.5% from 90.9%. Adjusted SG&A ratio 6.9% versus 7.1%.\n- On the 2026-07-28 call the FY2026 Medicaid composite rate forecast went to roughly 5% from roughly 4.5%; 2026 marketplace pretax margin guide 4.5%–5.0%, Medicare Part D pretax to more than 3% against an initial 2%.\n- Deleveraging is being executed in cash: total debt $16,105M at 2026-06-30 versus $17,401M at 2025-12-31 (Q2 10-Q); $1,289M of senior notes repurchased in H1; and the 2026-08-13 redemption retires another $500M at par.\n- Illinois re-procurement retained: subsidiary Meridian Health Plan of Illinois was awarded a HealthChoice Illinois contract announced 2026-07-09, four-year term from 2027-01-01 across all 102 counties, against a book of more than 596,000 current Medicaid enrollees.\n- KFF's 2026-08-03 review of 276 insurers across all 50 states and DC puts the median proposed 2027 marketplace increase at about 15%, with 63% of filings between 10% and 25% — repricing is industry-wide.\n\n## Bear Case\n\n- Volume is guided down: on 2026-07-28 the CEO said year-end membership would be lower than the prior outlook. Total at-risk membership was 25.9M at 2026-06-30 against 28.0M a year earlier.\n- The group is marked on enrollment, not on EPS. MOH beat and fell 12% on 2026-07-23; ELV's 2026-07-15 guidance raise set off a sector selloff; CNC's own 131% EPS surprise produced a 5.1% decline on 2026-07-28.\n- Q2 carried roughly $0.50 of prior-year settlement contribution (Q2 call, 2026-07-28), which does not repeat in Q3.\n- The enhanced premium tax credits expired 2025-12-31. Senate votes on competing extensions in December 2025 advanced nothing; the House passed HR 1834 230-196 on 2026-01-08; ASTHO's 2026-01-20 update described the Senate path as unclear, with a bipartisan CARE Act draft proposing a two-year extension plus minimum premium payments and income caps. No Senate passage has been reported since.\n- CMS projects its 2027 payment-parameters rule alone cuts marketplace enrollment by 1.2–2M, before pricing effects.\n- Twice-a-year Medicaid eligibility redeterminations begin in December 2026; the Urban Institute estimated on 2026-07-16 that 2–3.1M people could lose coverage. Centene carried 12.1M Medicaid members at quarter-end.\n- Part D premium stabilization was not renewed for 2027 (WSJ, 2026-07-28), under a book whose 2026 margin guide was just raised.\n- The only open-market insider transaction reported in 2026 is a sale: Director Kenneth A. Burdick, 80,000 shares at $64.55 ($5.164M), cutting his holding 22% to 283,580 shares (Form 4, 2026-06-11). Every other 2026 Form 4 is a zero-consideration award.\n\n## Setup & Price Structure\n\n- Sequence: $64.07 close on 2026-08-04, $65.77 close on 2026-08-07 (+2.45%). The 2026-08-04 session low of $63.48 was the fifth consecutive higher low since the print; RSI(14) read 49.97 that day (Barchart).\n\n- Overhead reference is the 52-week high of $69.36; the 52-week low is $25.08 (stockanalysis.com, 2026-08-07).\n- Positioning observables: eight target raises and zero cuts between 2026-07-28 and 2026-08-04; the high marks (Barclays $80 and Truist $80 on 2026-07-29, Bernstein $79 on 2026-08-03) sit above the $71.67 consensus while the newest sit within a few dollars of spot. Twelve of 21 ratings are Hold. Insider flow in 2026 is one sale and no purchases.\n- Capital return skews to bondholders: $33M of common stock repurchased in H1 against $1,289M of senior notes, plus the $500M par redemption dated 2026-08-13. No equity issuance into the rally is disclosed in the Q2 10-Q; 493,995 thousand shares were outstanding as of 2026-07-24.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-12** — CMS deadline, 3:00 p.m. EDT, for finalizing PY2027 rate filings containing a qualified health plan in HealthCare.gov-platform states.\n- **2026-08-13** — $500M partial redemption of the 4.25% notes due 2027-12-15, at 100% plus accrued; roughly $568,664,000 remains outstanding.\n- **2026-08-14** — Q2 2026 13F filing deadline.\n- **2026-09-08** — CMS review window for PY2027 QHP applications closes; certification agreements sent to issuers.\n\n## What Would Change Our Mind\n\nThe structure that has carried this since 2026-07-28 is the run of higher lows and the 50-day zone reclaimed on 2026-08-03. Losing that is the break: a weekly close below $63 undoes the reclaim measured at $63.85 on 2026-08-04 and ends the higher-low sequence; a weekly close below $56 additionally cuts under the July consolidation shelf and the post-print low. On the fundamental side, three observables would flip the read: 2026-08-12 passing with the 2027 rate position unchanged and no re-rating in the days after; a Q3 print (~2026-10-27, est.) that trims the more-than-$4.80 FY guide or leaves Medicaid HBR above the roughly 93.5% target it printed 93.9% against; or year-end membership landing materially below the Q2 marks of about 3.5M marketplace and 12.1M Medicaid.\n\nThe reverse case has an observable too. A Senate floor vote passing an enhanced-premium-tax-credit extension ahead of the November open-enrollment start would reset the 2027 volume assumption that the SATURATED label rests on, and would do it before any company disclosure.\n\n## Correlation Notes\n\n- CNC trades with the managed-care complex on policy headlines rather than on its own execution: ELV's 2026-07-15 raise moved the whole group lower, MOH fell 12% on 2026-07-23, and CNC fell 5.1% on its own beat on 2026-07-28.\n- Revenue is set by state Medicaid rate cycles and CMS rulemaking, so the regulatory calendar — 2026-08-12, 2026-09-08, the December redetermination start — carries more of the variance than quarterly execution.\n- With about 3.5M marketplace members at 2026-06-30, subsidy-legislation headlines hit CNC differently from Medicaid-weighted peers; conversely, the 12.1M Medicaid book ties it to the same December 2026 redetermination shock those peers face.\n- Premium and service revenue ran $44.4B in Q2 on a thin underwriting spread, so a percentage-point move in HBR swings EPS more than any single membership headline.",
  "first_seen": "2026-04-29",
  "last_analyzed": "2026-08-09T08:27:28+00:00",
  "last_synthesized": "2026-08-09",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}